SuperworthInvivyd IVVD
- Market cap
- $180.8M
- PE
- n/m
- a loss over the last year
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- 3.1×
- EV/EBIT
- n/m
- a loss over the last year
- Revenue, 12 months
- $58.4M
- +26% on a year ago
- Net margin
- n/m
- outside −100% to 100%
- Free cash flow yield
- −60.6%
Invivyd trades at 3.1× sales. Its trailing earnings are negative, so it has no PE. Revenue was $58.4M over the last twelve months, up 26% on a year earlier.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $0 | $0 | $0 | $2.3M | $9.3M | $13.8M | $11.3M | $11.8M+421% | $13.1M+41% | $17.2M+25% | $13.7M+22% | $14.3M+21% | |
| R&D | $25.6M−15% | $62.3M+213% | $31.2M+15% | $30.3M−31% | $57.9M+126% | $17.9M−71% | $10.6M−66% | $9.6M−68% | $8M−86% | $10M−44% | $30.7M+189% | $29.4M+207% |
| SG&A | $12.9M−2% | $15.1M+43% | $14.9M+35% | $21.1M+109% | $13M+1% | $14.4M−5% | $16.8M+12% | $16.6M−21% | $15M+16% | $18.6M+29% | $25.1M+50% | $29.5M+78% |
| −$43.1M−9% | −$76.8M+59% | −$46.1M+18% | −$49.2M−9% | −$62.3M+45% | −$19.2M−75% | −$16.9M−63% | −$15.1M−69% | −$11M−82% | −$12.6M−35% | −$43.1M+155% | −$45.8M+204% | |
| Net income | −$39.4M−13% | −$73.7M+65% | −$43.5M+23% | −$47.2M−6% | −$60.7M+54% | −$18.4M−75% | −$16.3M−63% | −$14.7M−69% | −$10.5M−83% | −$11.1M−40% | −$41.4M+154% | −$44.4M+203% |
| −$0.36−14% | −$0.67+63% | −$0.38+19% | −$0.40−13% | −$0.51+42% | −$0.15−78% | −$0.14−63% | −$0.12−70% | −$0.06−88% | −$0.04−73% | −$0.13−7% | −$0.14+17% | |
| 109.8M+1% | 110.1M+1% | 115.6M+6% | 119.4M+9% | 119.5M+9% | 119.7M+9% | 119.9M+4% | 120M+1% | 170.2M+42% | 277.1M+131% | 309.7M+158% | 320.4M+167% |
Net income: Q1 FY21: 6 months less the 3 months printed beside them.
EPS, diluted: 4 periods, Q4 FY22 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: 4 periods, Q4 FY22 to Q4 FY25: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Healthcare nearest Invivyd's size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| IVVDInvivyd | $180.8M | n/m | n/a | 3.1× | +26% | n/m | |
| PDEXPro DEX | $199.3M | 15.1× | 16.6× | 2.6× | +16% | 17.6% | |
| PLXProtalix BioTherapeutics | $205.5M | 11.1× | 34.2× | 2.5× | +30% | 23.5% | |
| NATRNatures Sunshine Products | $213.8M | 12.0× | 20.6× | 0.4× | +7% | 3.7% | |
| ELMDElectromed | $220.6M | 20.1× | 29.0× | 3.0× | +15% | 15.3% | |
| UTMDUtah Medical Products | $236.3M | 22.6× | 20.9× | 6.5× | −7% | 29.0% | |
| INFUInfuSystem | $277.6M | 34.0× | 43.5× | 1.9× | +2% | 6.0% | |
| KEQUKewaunee Scientific | $94.9M | 11.9× | 13.7× | 0.3× | +5% | 3.0% | |
| ICCCImmucell | $93.1M | 128× | 44.0× | 3.0× | +8% | 2.6% | |
| VMDViemed Healthcare | $373.3M | 27.2× | 26.1× | 1.2× | +25% | 4.8% | |
| EMBCEmbecta | $380.2M | 4.6× | 11.7× | 0.4× | −8% | 8.6% | |
| Peer median | $217.2M | 17.6× | 23.5× | 2.2× | +8% | 7.3% |
Investors who own it
Investors we follow who held Invivyd at the end of Jun 30, 2026, from their 13F filings.
- Lee AinslieMaverick Capital0.1% of portfolio
More on Invivyd
Each number over time
Its groups
About
- Industry
- Biotechnology
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .